Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBIT (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBIT for 8 consecutive years, with $85.2 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 549.56% to $85.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.3 million through Dec 2025, up 93.59% year-over-year, with the annual reading at -$4.3 million for FY2025, 93.59% up from the prior year.
  • EBIT for Q4 2025 was $85.2 million at Whitehawk Therapeutics, up from -$19.5 million in the prior quarter.
  • The five-year high for EBIT was $85.2 million in Q4 2025, with the low at -$87.3 million in Q3 2021.
  • Average EBIT over 5 years is -$15.9 million, with a median of -$16.4 million recorded in 2021.
  • The sharpest move saw EBIT plummeted 3178.67% in 2021, then surged 549.56% in 2025.
  • Over 5 years, EBIT stood at -$15.9 million in 2021, then rose by 2.97% to -$15.5 million in 2022, then dropped by 14.49% to -$17.7 million in 2023, then dropped by 6.97% to -$18.9 million in 2024, then soared by 549.56% to $85.2 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $85.2 million, -$19.5 million, and -$54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.